Kim Steegen to HIV-1
This is a "connection" page, showing publications Kim Steegen has written about HIV-1.
Connection Strength
4,050
-
Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries. AIDS. 2023 05 01; 37(6):1009-1011.
Score: 0,466
-
Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa. J Antimicrob Chemother. 2021 09 15; 76(10):2659-2665.
Score: 0,424
-
Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa. J Int AIDS Soc. 2021 05; 24(5):e25706.
Score: 0,413
-
Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS One. 2016; 11(12):e0166305.
Score: 0,304
-
Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa. J Infect Dis. 2016 Dec 15; 214(12):1826-1830.
Score: 0,302
-
HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. J Antimicrob Chemother. 2017 01; 72(1):210-219.
Score: 0,300
-
High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. PLoS One. 2014; 9(5):e97067.
Score: 0,254
-
Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings. J Virol Methods. 2007 Dec; 146(1-2):178-87.
Score: 0,159
-
Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots. J Clin Microbiol. 2007 Oct; 45(10):3342-51.
Score: 0,159
-
A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J Virol Methods. 2006 May; 133(2):137-45.
Score: 0,142
-
Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir. Viruses. 2024 12 06; 16(12).
Score: 0,132
-
K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine. Viruses. 2024 Sep 20; 16(9).
Score: 0,130
-
Recommendations on data sharing in HIV drug resistance research. PLoS Med. 2023 Sep; 20(9):e1004293.
Score: 0,122
-
Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV. 2018 11; 5(11):e638-e646.
Score: 0,086
-
Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. J Antimicrob Chemother. 2016 10; 71(10):2918-27.
Score: 0,074
-
High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa. PLoS One. 2015; 10(2):e0118145.
Score: 0,067
-
Performance and logistical challenges of alternative HIV-1 virological monitoring options in a clinical setting of Harare, Zimbabwe. Biomed Res Int. 2014; 2014:102598.
Score: 0,064
-
Viral tropism and antiretroviral drug resistance in HIV-1 subtype C-infected patients failing highly active antiretroviral therapy in Johannesburg, South Africa. AIDS Res Hum Retroviruses. 2014 Mar; 30(3):289-93.
Score: 0,062
-
Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol. J Virol Methods. 2013 Dec; 194(1-2):300-7.
Score: 0,061
-
A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only. J Clin Microbiol. 2013 Jun; 51(6):1757-61.
Score: 0,059
-
HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone. PLoS One. 2012; 7(4):e34708.
Score: 0,055
-
A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay. PLoS One. 2011; 6(5):e19643.
Score: 0,052
-
Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. J Virol Methods. 2010 Feb; 163(2):253-7.
Score: 0,046
-
Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob Agents Chemother. 2009 May; 53(5):2185-8.
Score: 0,044
-
Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes. J Virol Methods. 2005 Sep; 128(1-2):47-53.
Score: 0,035
-
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine. 2017 Apr; 18:225-235.
Score: 0,019
-
Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa. Trop Med Int Health. 2016 09; 21(9):1131-7.
Score: 0,018